Radiopharmaceuticals have been used for the treatment of various forms of cancer since the 1940s. In recent years, the advantages of alpha emitting radionuclides have emerged as a favourable treatment option. However, most alpha emitting radionuclides have long decay chains with long-lived daughter radionuclides. This leads to uncertainties in the dosimetry for normal organs and tissues, when established dosimetry models are employed. The aim of this project is to assign each progeny its own biokinetic behaviour. The novel dosimetry model was applied to 223Ra-dichloride, frequently used for the treatment of patients with metastatic bone disease from castration-resistant prostate cancer. In this dosimetry model, individual biokinetics for each daughter radionuclide was included. This resulted in a decrease in absorbed dose to bone surfaces and red marrow and increased absorbed dose to liver and kidney, when compared with dosimetry models assuming that the daughter nuclides follow the biokinetics of the parent radionuclide.

中文翻译：

---

IDAC-ALPHA：用于正常器官和组织的 ALPHA 剂量测量软件

自 1940 年代以来，放射性药物已被用于治疗各种形式的癌症。近年来，α发射放射性核素的优势已成为一种有利的治疗选择。然而，大多数 α 发射放射性核素具有长衰变链和长寿命子放射性核素。当使用已建立的剂量测定模型时，这会导致正常器官和组织的剂量测定存在不确定性。该项目的目的是为每个后代分配其自己的生物动力学行为。新的剂量学模型应用于 223Ra-二氯化物，常用于治疗去势抵抗性前列腺癌转移性骨病患者。在这个剂量学模型中，包括了每个子放射性核素的个体生物动力学。